A pivotal phase II/III study of TD213 in patients infected with COVID-19
Latest Information Update: 13 Jul 2022
Price :
$35 *
At a glance
- Drugs Probenecid (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors TrippBio
- 27 Oct 2020 New trial record